437 related articles for article (PubMed ID: 18287214)
1. Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia.
Schmidt CJ; Chapin DS; Cianfrogna J; Corman ML; Hajos M; Harms JF; Hoffman WE; Lebel LA; McCarthy SA; Nelson FR; Proulx-LaFrance C; Majchrzak MJ; Ramirez AD; Schmidt K; Seymour PA; Siuciak JA; Tingley FD; Williams RD; Verhoest PR; Menniti FS
J Pharmacol Exp Ther; 2008 May; 325(2):681-90. PubMed ID: 18287214
[TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia.
Grauer SM; Pulito VL; Navarra RL; Kelly MP; Kelley C; Graf R; Langen B; Logue S; Brennan J; Jiang L; Charych E; Egerland U; Liu F; Marquis KL; Malamas M; Hage T; Comery TA; Brandon NJ
J Pharmacol Exp Ther; 2009 Nov; 331(2):574-90. PubMed ID: 19661377
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis.
Siuciak JA; Chapin DS; Harms JF; Lebel LA; McCarthy SA; Chambers L; Shrikhande A; Wong S; Menniti FS; Schmidt CJ
Neuropharmacology; 2006 Aug; 51(2):386-96. PubMed ID: 16780899
[TBL] [Abstract][Full Text] [Related]
4. Chronic suppression of phosphodiesterase 10A alters striatal expression of genes responsible for neurotransmitter synthesis, neurotransmission, and signaling pathways implicated in Huntington's disease.
Kleiman RJ; Kimmel LH; Bove SE; Lanz TA; Harms JF; Romegialli A; Miller KS; Willis A; des Etages S; Kuhn M; Schmidt CJ
J Pharmacol Exp Ther; 2011 Jan; 336(1):64-76. PubMed ID: 20923867
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia.
Verhoest PR; Chapin DS; Corman M; Fonseca K; Harms JF; Hou X; Marr ES; Menniti FS; Nelson F; O'Connor R; Pandit J; Proulx-Lafrance C; Schmidt AW; Schmidt CJ; Suiciak JA; Liras S
J Med Chem; 2009 Aug; 52(16):5188-96. PubMed ID: 19630403
[TBL] [Abstract][Full Text] [Related]
6. Alterations in gene regulation following inhibition of the striatum-enriched phosphodiesterase, PDE10A.
Strick CA; James LC; Fox CB; Seeger TF; Menniti FS; Schmidt CJ
Neuropharmacology; 2010 Feb; 58(2):444-51. PubMed ID: 19765598
[TBL] [Abstract][Full Text] [Related]
7. The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey.
Smith SM; Uslaner JM; Cox CD; Huszar SL; Cannon CE; Vardigan JD; Eddins D; Toolan DM; Kandebo M; Yao L; Raheem IT; Schreier JD; Breslin MJ; Coleman PJ; Renger JJ
Neuropharmacology; 2013 Jan; 64():215-23. PubMed ID: 22750078
[TBL] [Abstract][Full Text] [Related]
8. Patterns of brain glucose metabolism induced by phosphodiesterase 10A inhibitors in the mouse: a potential translational biomarker.
Dedeurwaerdere S; Wintmolders C; Vanhoof G; Langlois X
J Pharmacol Exp Ther; 2011 Oct; 339(1):210-7. PubMed ID: 21742809
[TBL] [Abstract][Full Text] [Related]
9. Phosphodiesterase 10A in the rat pineal gland: localization, daily and seasonal regulation of expression and influence on signal transduction.
Spiwoks-Becker I; Wolloscheck T; Rickes O; Kelleher DK; Rohleder N; Weyer V; Spessert R
Neuroendocrinology; 2011; 94(2):113-23. PubMed ID: 21474921
[TBL] [Abstract][Full Text] [Related]
10. Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia.
Menniti FS; Chappie TA; Humphrey JM; Schmidt CJ
Curr Opin Investig Drugs; 2007 Jan; 8(1):54-9. PubMed ID: 17263185
[TBL] [Abstract][Full Text] [Related]
11. Phosphodiesterase 10A inhibition is associated with locomotor and cognitive deficits and increased anxiety in mice.
Hebb AL; Robertson HA; Denovan-Wright EM
Eur Neuropsychopharmacol; 2008 May; 18(5):339-63. PubMed ID: 17913473
[TBL] [Abstract][Full Text] [Related]
12. Behavioral characterization of mice deficient in the phosphodiesterase-10A (PDE10A) enzyme on a C57/Bl6N congenic background.
Siuciak JA; McCarthy SA; Chapin DS; Martin AN; Harms JF; Schmidt CJ
Neuropharmacology; 2008 Feb; 54(2):417-27. PubMed ID: 18061215
[TBL] [Abstract][Full Text] [Related]
13. PDE10A inhibitors: an assessment of the current CNS drug discovery landscape.
Chappie T; Humphrey J; Menniti F; Schmidt C
Curr Opin Drug Discov Devel; 2009 Jul; 12(4):458-67. PubMed ID: 19562642
[TBL] [Abstract][Full Text] [Related]
14. Antipsychotic-like effects of a novel phosphodiesterase 10A inhibitor T-251 in rodents.
Takakuwa M; Watanabe Y; Tanaka K; Ishii T; Kagaya K; Taniguchi H; Kotera J; Hashimoto K
Pharmacol Biochem Behav; 2019 Oct; 185():172757. PubMed ID: 31404565
[TBL] [Abstract][Full Text] [Related]
15. Increased social interaction in mice deficient of the striatal medium spiny neuron-specific phosphodiesterase 10A2.
Sano H; Nagai Y; Miyakawa T; Shigemoto R; Yokoi M
J Neurochem; 2008 Apr; 105(2):546-56. PubMed ID: 18088367
[TBL] [Abstract][Full Text] [Related]
16. Phosphodiesterase 10A inhibition modulates the sensitivity of the mesolimbic dopaminergic system to D-amphetamine: involvement of the D1-regulated feedback control of midbrain dopamine neurons.
Sotty F; Montezinho LP; Steiniger-Brach B; Nielsen J
J Neurochem; 2009 May; 109(3):766-75. PubMed ID: 19236563
[TBL] [Abstract][Full Text] [Related]
17. PDE10A and PDE10A-dependent cAMP catabolism are dysregulated oppositely in striatum and nucleus accumbens after lesion of midbrain dopamine neurons in rat: a key step in parkinsonism physiopathology.
Giorgi M; Melchiorri G; Nuccetelli V; D'Angelo V; Martorana A; Sorge R; Castelli V; Bernardi G; Sancesario G
Neurobiol Dis; 2011 Jul; 43(1):293-303. PubMed ID: 21515371
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, SAR study, and biological evaluation of novel quinoline derivatives as phosphodiesterase 10A inhibitors with reduced CYP3A4 inhibition.
Hamaguchi W; Masuda N; Miyamoto S; Shiina Y; Kikuchi S; Mihara T; Moriguchi H; Fushiki H; Murakami Y; Amano Y; Honbou K; Hattori K
Bioorg Med Chem; 2015 Jan; 23(2):297-313. PubMed ID: 25515954
[TBL] [Abstract][Full Text] [Related]
19. Discovery of 1-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one (TAK-063), a highly potent, selective, and orally active phosphodiesterase 10A (PDE10A) inhibitor.
Kunitomo J; Yoshikawa M; Fushimi M; Kawada A; Quinn JF; Oki H; Kokubo H; Kondo M; Nakashima K; Kamiguchi N; Suzuki K; Kimura H; Taniguchi T
J Med Chem; 2014 Nov; 57(22):9627-43. PubMed ID: 25384088
[TBL] [Abstract][Full Text] [Related]
20. In vivo pharmacological characterization of TAK-063, a potent and selective phosphodiesterase 10A inhibitor with antipsychotic-like activity in rodents.
Suzuki K; Harada A; Shiraishi E; Kimura H
J Pharmacol Exp Ther; 2015 Mar; 352(3):471-9. PubMed ID: 25525190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]